Instrument Inactif

Communiqués CELLCEUTIX OTC Bulletin Board

Actions

CTIX

US15115V1017

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

01/02	Innovation Pharmaceuticals Inc. annonce la démission de membres de son conseil d'administration	CI
2023	Alfasigma S.p.A. et Innovation Pharmaceuticals Inc. mettent fin à l'accord de licence exclusive	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024	28/08/23	AQ
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	21/06/23	AQ
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing	05/06/23	AQ
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications	17/04/23	AQ
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers	15/03/23	AQ
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission	23/02/23	AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	15/02/23	AQ
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement	09/01/23	AQ
INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)	04/01/23	AQ
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis	14/12/22	AQ
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis	13/12/22	AQ
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family	28/11/22	AQ
Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference	16/11/22	AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	10/11/22	AQ
Innovation Pharmaceuticals - NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy 'Game-Changing Breakthrough'	27/10/22	AQ
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"	26/10/22	AQ
Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin	04/10/22	AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	28/09/22	AQ
New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals Brilacidin Presented at 2022 Military Health System Research Symposium	16/09/22	AQ
Innovation Pharmaceuticals Investment in BT BeaMedical Helping Advance New Surgical Laser Platform	14/09/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CELLCEUTIX OTC Bulletin Board

Actions

CTIX

US15115V1017

Communiqués

Filtres